A class action lawsuit has been initiated against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging the financial institutions engaged in market manipulation schemes involving Quantum Biopharma Ltd. securities. According to the complaint, the banks allegedly placed spoofed sell orders—a practice involving the placement of non-bona fide orders intended to create misleading impressions of market activity—to artificially depress the company's stock price before acquiring shares at artificially reduced levels.
The litigation targets investors who liquidated Quantum Biopharma securities during a nearly five-year period spanning from January 6, 2021, through October 15, 2025. The lawsuit contends that affected shareholders sustained losses due to the alleged manipulation tactics, which allegedly allowed the defendant banks to profit from artificially suppressed pricing. Legal representatives are actively seeking eligible investors to participate in the class action proceedings.
The case represents a significant enforcement action against institutional market participants and highlights ongoing regulatory scrutiny regarding market manipulation practices. Such allegations underscore the importance of market surveillance mechanisms designed to detect and prevent spoofing and other disruptive trading practices in securities markets.